On July 15, Erasca rose 5.41% in regular trading, trading at $20.48/share, with turnover of approximately $43.34 million. The stock rebounded sharply as investors digested positive clinical developments disclosed the prior session.

The rally was driven by updated preliminary Phase 1 data for its potentially best-in-class pan-RAS molecular glue ERAS-0015 in KRAS-mutant solid tumors, along with a clear registration pathway. The company announced plans to initiate a registration-enabling lung cancer trial in the first half of 2027 and a pivotal Phase 3 pancreatic cancer trial also slated for 2027, marking a significant advancement in its oncology pipeline.

Notably, Erasca simultaneously announced a proposed $500 million underwritten public offering of common stock, with underwriters granted a 30-day option to purchase up to an additional $75 million in shares. The stock had initially declined 3.5% in after-hours trading on July 14 on dilution concerns, but the strength of the clinical catalysts ultimately outweighed financing overhang during the following regular session.

Erasca is a clinical-stage precision oncology company focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)